A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
Ann Neurol
.
2014 Aug;76(2):185-205.
doi: 10.1002/ana.24188.
Epub 2014 Jul 2.
Authors
Eric Karran
1
,
John Hardy
Affiliation
1
Alzheimer's Research UK, Cambridge; Reta Lila Weston Laboratories, London; Department of Molecular Neuroscience, University College London, London, United Kingdom.
PMID:
24853080
PMCID:
PMC4204160
DOI:
10.1002/ana.24188
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Review
MeSH terms
Alzheimer Disease / drug therapy*
Clinical Trials, Phase III as Topic / standards*
Drug Discovery / standards*
Humans
Plaque, Amyloid / drug therapy*
Grant support
089698/Wellcome Trust/United Kingdom
MC_G1000735/Medical Research Council/United Kingdom